Management of the upper limb in cerebral palsy

被引:59
作者
Chin, TYP
Duncan, JA
Johnstone, BR
Graham, HK
机构
[1] Royal Childrens Hosp, Dept Orthopaed, Parkville, Vic 3052, Australia
[2] Royal Childrens Hosp, Dept Occupat Therapy, Parkville, Vic 3052, Australia
[3] Royal Childrens Hosp, Dept Plast & Reconstruct Surg, Parkville, Vic 3052, Australia
[4] Royal Childrens Hosp, Hugh Williamson Gait Anal Lab, Parkville, Vic 3052, Australia
[5] Univ Melbourne, Melbourne, Vic, Australia
来源
JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B | 2005年 / 14卷 / 06期
关键词
cerebral palsy; spasticity; dystonia; deformity; contracture; botulinum toxin A; occupational therapy; physiotherapy; surgery;
D O I
10.1097/01202412-200511000-00001
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
The management of the upper limb in cerebral palsy is often complex and challenging. Effective treatment requires a multidisciplinary approach involving paediatricians, occupational therapists, physiotherapists, orthotists and upper extremity surgeons. Interventions are generally aimed at improving function and cosmesis by spasticity management, preventing contractures and correcting established deformities. Treatment objectives vary according to each child and range from static correction of deformities to ease nursing care, to improvements in dynamic muscle balance to augment hand function. Botulinum toxin A therapy has been shown to relieve spasticity and improve function in the short term. Surgery is also effective but requires careful patient selection, as many children with cerebral palsy are not candidates for surgery. Occupational therapy and physiotherapy have small treatment effects alone but are essential adjuncts to medical and surgical management.
引用
收藏
页码:389 / 404
页数:16
相关论文
共 66 条
[1]  
[Anonymous], 2000, CLIN DEV MED
[2]   Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions [J].
Aoki, KR ;
Guyer, B .
EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 :21-29
[3]   Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury:: clinical implications [J].
Autti-Rämö, I ;
Larsen, A ;
Taimo, A ;
von Wendt, L .
EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 :136-144
[4]   (ii) The management of spastic diplegia [J].
Bache, CE ;
Selber, P ;
Graham, HK .
CURRENT ORTHOPAEDICS, 2003, 17 (02) :88-104
[5]   Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial [J].
Barwood, S ;
Baillieu, C ;
Boyd, R ;
Brereton, K ;
Low, J ;
Nattrass, G ;
Graham, HK .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2000, 42 (02) :116-121
[6]  
Berweck S, 2003, HDB BOTULINUM TOXIN, P272
[7]  
BOEHME R, 1988, IMPROVING UPPER BODY
[8]   INTERRATER RELIABILITY OF A MODIFIED ASHWORTH SCALE OF MUSCLE SPASTICITY [J].
BOHANNON, RW ;
SMITH, MB .
PHYSICAL THERAPY, 1987, 67 (02) :206-207
[9]   Medium-term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy [J].
Boyd, RN ;
Graham, JEA ;
Nattrass, GR ;
Graham, HK .
EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 :S37-S45
[10]   Management of upper limb dysfunction in children with cerebral palsy: a systematic review [J].
Boyd, RN ;
Morris, ME ;
Graham, HK .
EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 :150-166